Breaking News Instant updates and real-time market news.

MDB

MongoDB

$104.33

-0.54 (-0.51%)

, MLNT

Melinta Therapeutics

$4.84

0.075 (1.57%)

19:02
03/13/19
03/13
19:02
03/13/19
19:02

Fly Intel: After Hours Movers

UP AFTER EARNINGS: MongoDB (MDB) up 19.2%... Melinta Therapeutics (MLNT) up 15.7%... Domo (DOMO) up 13.0%... Fluent (FLNT) up 6.8%... Village Farms (VFF) up 3.9%. ALSO HIGHER: ID Systems (IDSY) up 15.1% after acquiring Pointer Telocation (PNTR), which was also up 10.7%. DOWN AFTER EARNINGS: Tailored Brands (TLRD) down 17.8%... Cloudera (CLDR) down 13.7%... Kingstone Companies (KINS) down 8.1%... Semtech (SMTC) down 7.2%... Smart & Final Stores (SFS) down 5.6%... Applied Motion (AMOT) down 5.2%... GDS Holdings (GDS) down 4.7%... Viking Therapeutics (VKTX) down 3.8%... Abraxas Petroleum (AXAS) down 3.0%. ALSO LOWER: Legacy Reserves (LGCY) down 25.9% after announcing review of strategic alternatives... Roadrunner (RRTS) down 5.0% after 1-for-25 reverse stock split. Movers as of 18:45ET.

MDB

MongoDB

$104.33

-0.54 (-0.51%)

MLNT

Melinta Therapeutics

$4.84

0.075 (1.57%)

DOMO

Domo

$31.24

0.73 (2.39%)

FLNT

Fluent

$5.89

0.14 (2.43%)

VFF

Village Farms

$12.75

-0.32 (-2.45%)

IDSY

I.D. Systems

$6.33

0.04 (0.64%)

PNTR

Pointer Telocation

$14.49

-0.1 (-0.69%)

TLRD

Tailored Brands

$11.67

-0.33 (-2.75%)

CLDR

Cloudera

$14.62

0.27 (1.88%)

KINS

Kingstone Companies

$16.16

0.17 (1.06%)

SMTC

Semtech

$55.50

0.89 (1.63%)

SFS

Smart & Final Stores

$6.34

0.15 (2.42%)

AMOT

Allied Motion

$41.68

0.42 (1.02%)

GDS

GDS Holdings

$35.06

-0.38 (-1.07%)

VKTX

Viking Therapeutics

$8.25

0.28 (3.51%)

AXAS

Abraxas Petroleum

$1.34

0.07 (5.51%)

LGCY

Legacy Reserves

$1.39

0.12 (9.45%)

RRTS

Roadrunner

$0.49

-0.0058 (-1.18%)

  • 13

    Mar

  • 13

    Mar

  • 13

    Mar

  • 13

    Mar

  • 13

    Mar

  • 13

    Mar

  • 13

    Mar

  • 13

    Mar

  • 13

    Mar

  • 13

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 14

    Mar

  • 14

    Mar

  • 14

    Mar

  • 19

    Mar

  • 19

    Mar

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 25

    Mar

  • 04

    Apr

  • 10

    Apr

  • 28

    May

  • 15

    Mar

MDB MongoDB
$104.33

-0.54 (-0.51%)

01/11/19
DADA
01/11/19
NO CHANGE
Target $80
DADA
Neutral
Competitive concerns on MongoDB from Amazon may be overblown, says DA Davidson
DA Davidson analyst Rishi Jaluria kept his Neutral rating and $80 price target on MongoDB (MDB) following the Amazon (AMZN) AWS announcement of the launch of DocumentDB that supports MongoDB workloads. The analyst contents that the move is not surprising given the AWS pattern of moving "up the stack" over time. Jaluria also notes that the company has faced a similar threat in the past with Azure Cosmos DB's API for MongoDB, but believes that the company's MongoDB Atlas was not impacted. Further, the analyst ponders whether Amazon's attempt to undercut MongoDB sets up a potential bid for the company.
02/28/19
NEED
02/28/19
NO CHANGE
Target $108
NEED
Buy
MongoDB price target raised to $108 from $97 at Needham
Needham analyst Jack Andrews raised his price target on MongoDB to $108 and kept his Buy rating, saying the 9% decline in the stock price on Tuesday on press speculation regarding Lyft migrating its database needs towards AWS was unfounded. The analyst contends that the shift would be a "highly implausible scenario", since his research indicates that DocumentDB is more comparable to a 6 year old version of MongoD product and thus would be "unlikely to meet Lyft's performance and scalability requirements".
02/26/19
NOMU
02/26/19
NO CHANGE
Target $63
NOMU
Reduce
Lyft may be making 'massive' migration away from MongoDB, says Nomura Instinet
Nomura Instinet analyst Christopher Eberle said he recently discovered that Lyft (LYFT) is "quite dissatisfied" with MongoDB's (MDB) performance and he believes the ride-sharing service operator is in the process of a "massive database migration," he told investors in a research note. While he has not yet identified who Lyft is migrating to, based on industry conversations Eberle thinks it could be either Amazon Web Services' (AMZN) DynamoDB or Google (GOOGL) Spanner, he noted. The analyst, who continues to see risks from increased availability of viable competitive solutions and the introduction of SSPL, keeps a Reduce rating and $63 price target on MongoDB shares, which are down 2% in early trading.
01/10/19
RSBL
01/10/19
NO CHANGE
RSBL
MongoDB shares defended at Rosenblatt
MLNT Melinta Therapeutics
$4.84

0.075 (1.57%)

10/22/18
10/22/18
UPGRADE

Melinta Therapeutics upgraded to Buy on valuation at Gabelli
As previously reported, Gabelli upgraded Melinta Therapeutics to Buy from Neutral citing valuation.
12/20/18
GABE
12/20/18
DOWNGRADE
Target $1.5
GABE
Hold
Melinta Therapeutics downgraded to Hold from Buy at Gabelli
Gabelli analyst Kevin Kedra downgraded Melinta Therapeutics to Hold from Buy after the company announced a commitment for $135M of 5% convertible loans from top shareholder Vatera, stating that in agreeing to the new financing Vatera has "moved the goalposts." Vatera's convertible preferred structure will make them a de-facto majority owner and give them a preferred position ahead of common shareholders in any liquidation event, Kedra stated. He also cites industry-wide struggles for antibiotic companies. Kedra lowered his 2019 PMV for Melinta to $1.50 from $6.00 per share.
11/01/18
HCWC
11/01/18
NO CHANGE
Target $13
HCWC
Buy
Melinta Therapeutics target raised to $13 on 'clean win' at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Melinta Therapeutics to $13 from $12 citing the company's positive top-line results of its Phase 3 pivotal study of Baxdela compared to moxifloxacin for the treatment of adults with community acquired bacteria pneumonia. The analyst views the data as a "clean win" and thinks it likely cues up a key label expansion by the end of 2019. He raised his probability of success for community acquired bacteria pneumonia to 85% from 65% and keeps a Buy rating on Melinta.
10/22/18
HCWC
10/22/18
NO CHANGE
Target $12
HCWC
Buy
Melinta CEO departure not business related, says H.C. Wainwright
After speaking to the company, H.C. Wainwright analyst Ed Arce says the "abrupt" departure of Melinta Therapeutics CEO Dan Wechsler "was mutual and involved nothing business related." Further, the analyst encouraged that the board, in appointing director John Johnson as interim CEO, has selected a 35-year industry veteran with "extensive executive experience." Arce lowered his price target for Melinta Therapeutics to $12 from $14 and affirms a Buy rating on the name.
DOMO Domo
$31.24

0.73 (2.39%)

01/14/19
NEED
01/14/19
INITIATION
Target $27
NEED
Buy
Domo initiated with a Buy at Needham
Needham analyst Jack Andrews initiated Domo with a Buy rating and a price target of $27, saying the company delivers a "complete Business Intelligence solution" at the lowest total cost of ownership. The analyst adds that Domo offers a wide breadth of functionality in its platform, the "self-service and scalability" of which should allow to meet its users' future requirements of enterprise analytics "without the exorbitant costs of implementation." Andrews is also positive on Domo's valuation with its stock trading at enterprise value to expected 2019 revenue multiple of 2.9-times - a discount relative to the Big Data software peer group that he expects to be closed.
01/14/19
01/14/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. SMTC Corp. (SMTX) initiated with a Buy at Craig-Hallum. 2. Carvana (CVNA) initiated with an Underweight at Morgan Stanley. 3. Linde plc (LIN) initiated with an Overweight at KeyBanc. 4. Domo (DOMO) initiated with a Buy at Needham. 5. Mercantil Bank (AMTB) initiated with an Outperform at Raymond James and Keefe Bruyette, and an Equal Weight at Stephens. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/07/19
MSCO
03/07/19
NO CHANGE
Target $38
MSCO
Overweight
Domo shares still have 'room to run,' says Morgan Stanley
Morgan Stanley analyst Sanjit Singh said he thinks Domo's enterprise pivot is gathering momentum and he still sees the stock having "room to run" despite its roughly 60% advance year-to-date. Management's repeated statements, including at the Morgan Stanley TMT conference, that the company will not need to raise additional capital has helped ignite a rally and he believes the re-rating process is likely to continue, Singh tells investors. The analyst, who thinks Domo should be able to top consensus billings expectations in Q4 and sees consensus FY20 subscription revenue expectations of 25% growth as achievable, raised his price target on Domo shares to $38 from $29 ahead of the company's upcoming Q4 report. He maintains an Overweight rating on the shares.
03/12/19
NEED
03/12/19
NO CHANGE
Target $37
NEED
Buy
Domo price target raised to $37 from $27 at Needham
Needham analyst Jack Andrews raised his price target on Domo to $37 and kept his Buy rating ahead of its Q4 results tomorrow, saying its "positive signals from its unfolding enterprise playbook" should result in a "solid quarter". The analyst is constructive on the company's "unique platform levered to the future requirements of enterprise analytics" without the high cost of implementation. Andrews adds that an independent cost-benefit study of the company's existing customers demonstrated that the adoption of Domo's platform generated a 434% return on investment.
FLNT Fluent
$5.89

0.14 (2.43%)

04/12/18
BRRR
04/12/18
INITIATION
Target $4
BRRR
Outperform
Fluent initiated with an Outperform at Barrington
Barrington analyst James Goss noted that Cogint (COGT) announced it will change its name to Fluent (FLNT) as the culmination of recent strategic changes at the company, including the spin off of Red Violet (RDVT). He has established an Outpeform rating and $4 price target on Fluent shares, which are expected to begin trading at market open on Monday, April 16, according to the company. Goss said Fluent's revenue and cash flow generation are appealing and his $4 target "uses a conservative EBITDA multiple of under 10x," he noted.
VFF Village Farms
$12.75

-0.32 (-2.45%)

IDSY I.D. Systems
$6.33

0.04 (0.64%)

03/28/18
LTCO
03/28/18
INITIATION
Target $10
LTCO
Buy
I.D. Systems initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Glenn Mattson started I.D. Systems with a Buy rating and $10 price target.
12/06/18
LSCM
12/06/18
NO CHANGE
LSCM
I.D. Systems expansion with Avis provides multiple benefits, says Lake Street
Lake Street analyst Jaeson Schmidt reiterated a Buy rating and $9.50 price target on I.D. Systems (IDSY) after the company expanded its relationship with Avis (CAR) with a new 75K unit order. Schmidt believes the expansion has three key benefits for I.D. Systems -- It should be additive to the P&L as he estimates its value at over $30M, it was not a one-off order and he would not be surprised if the relationship was further expanded, and concerns on tough year-over-year comparisons should lessen.
08/27/18
NATL
08/27/18
INITIATION
Target $8.6
NATL
Buy
I.D. Systems initiated with a Buy at National Securities
National Securities analyst Matthew Galinko started I.D. Systems with a Buy rating and $8.60 price target. The company is an "unsung contender" in the market for Industrial Internet of Things, Galinko tells investors in a research note. He believes the company has a "significant platform" selling fleet telematics, with an increasing focus on logistics visibility as well as a market leading position in industrial truck management. I.D. Systems offers "positive trends in play across all segments and profitability emerging," Galinko contends.
PNTR Pointer Telocation
$14.49

-0.1 (-0.69%)

TLRD Tailored Brands
$11.67

-0.33 (-2.75%)

12/18/18
RILY
12/18/18
INITIATION
Target $20
RILY
Buy
Tailored Brands initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Susan Anderson started Tailored Brands with a Buy rating and $20 price target. The analyst believes the company is well positioned for a business turnaround.
12/13/18
DBAB
12/13/18
NO CHANGE
Target $24
DBAB
Hold
Tailored Brands price target lowered to $24 from $29 at Deutsche Bank
Deutsche Bank analyst Paul Trussell lowered his price target for Tailored Brands to $24 saying that while Q3 results were "solid," trends slowed at Men's Wearhouse in late October and throughout November leading to a negative revision to the fiscal 2018 forecast. The analyst believes investors will view the results "very unfavorably" and question future earnings power of the brand until Men's Wearhouse stabilizes. He keeps a Hold rating on the name.
10/08/18
JEFF
10/08/18
NO CHANGE
Target $40
JEFF
Buy
Tailored Brands shares to go higher on multiple expansion, says Jefferies
After meeting with management, Jefferies analyst Randal Konik says he continues to believe Tailored Brands shares will be driven higher by a mix of multiple expansion and earnings revisions. The company is on a path toward sustainable improvement, while legacy balance sheet issues are in the rearview, Konik tells investors in a research note titled "MET WITH MGMT: This Stock Is Custom Tailored For Your Portfolio." He keeps a Buy rating on the shares with a $40 price target.
12/18/18
12/18/18
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Logitech (LOGI) initiated with an Outperform at Wedbush. 2. Alnylam (ALNY) initiated with a Buy at Guggenheim, while BioMarin (BMRN) was initiated with a Neutral. 3. Tailored Brands (TLRD) initiated with a Buy at B. Riley FBR. 4. Adecogro (AGRO) initiated with a Neutral at Citi. 5. Shopify (SHOP) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CLDR Cloudera
$14.62

0.27 (1.88%)

03/12/19
MSCO
03/12/19
INITIATION
Target $16
MSCO
Equal Weight
Cloudera resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Sanjit Singh resumed coverage of Cloudera with an Equal Weight rating and $16 price target following its merger with Hortonworks. There is "plenty to like about the combination," including the fact that it created the largest, public open source data management company, but Singh sees near-term integration risks and has concerns about on-premises growth and lack of material cloud revenue, he noted.
03/11/19
LEHM
03/11/19
INITIATION
Target $16
LEHM
Equal Weight
Cloudera initiated with an Equal Weight at Barclays
Barclays analyst Raimo Lenschow started Cloudera with an Equal Weight rating and $16 price target.
11/09/18
RSBL
11/09/18
UPGRADE
RSBL
Buy
Cloudera upgraded to Buy from Neutral at Rosenblatt
01/09/19
NORL
01/09/19
INITIATION
Target $15
NORL
Outperform
Cloudera initiated with an Outperform at Northland
Northland analyst Tim Klasell initiated Cloudera with an Outperform and $15 price target saying he expect the company to emerge from the merger with Hortonworks with a broader product set, greater economies of scale and a leading position in open source data management.
KINS Kingstone Companies
$16.16

0.17 (1.06%)

SMTC Semtech
$55.50

0.89 (1.63%)

11/29/18
LOOP
11/29/18
NO CHANGE
Target $60
LOOP
Buy
Semtech enduring mobile weakness with no sign of contagion, says Loop Capital
Loop Capital analyst Cody Acree kept his Buy rating and $60 price target on Semtech, saying that while the company is exposed to the slowdown of global demand for smartphones, it is not experiencing a decline in activity in other businesses. The analyst notes that other larger semiconductor names have signaled a tightening of orders, but Semtech appears to be benefiting from the "multiple company-specific drivers that are helping to insulate it from larger macro concerns." Acree adds that he is most encouraged by the company's LoRa Internet of Things platform that is building global momentum by nearly doubling relative to last year and also cites the Data Center optical upgrades to 100G as a solid driver for Semtech.
11/29/18
RBCM
11/29/18
NO CHANGE
Target $55
RBCM
Outperform
Semtech price target lowered to $55 from $60 at RBC Capital
RBC Capital analyst Mitch Steves lowered his price target on Semtech to $55, saying that while the company beat on Q3 earnings, its Q4 guidance came in "a bit light", particularly on the top line. The analyst maintains his Outperform rating however, noting that the sales shortfall was in line with his expectations based on the smartphone market weakness. Steves points to continued improvement in margins as a sign that Semtech sales mix is "moving in the correct direction".
12/06/18
SUSQ
12/06/18
INITIATION
Target $54
SUSQ
Neutral
Semtech initiated with a Neutral at Susquehanna
Susquehanna analyst Chris Roland initiated Semtech with a Neutral rating and a price target of $54. The analyst states that the stock represents a "powerful way for investors to gain Internet of Things exposure", but also sees its valuation at an estimated over 15-times enterprise value to trailing 12 months sales as "not cheap".
01/08/19
PIPR
01/08/19
NO CHANGE
PIPR
Piper names Broadcom, Marvell, Semtech top 2019 Semi picks
Mid-to-long-term investors should start looking to initiate positions in Semiconductor stocks, Piper Jaffray analyst Harsh Kumar tells investors in a research note. The analyst, however, expects the "extreme volatility" in the stock to continue over the next few months due to March quarter guidance likely being impacted by a slower China and the timing of a trade war deal. Amid his backdrop, his top picks for 2019 are Broadcom (AVGO), Marvell Technology (MRVL) and Semtech (SMTC).
SFS Smart & Final Stores
$6.34

0.15 (2.42%)

02/07/19
BUCK
02/07/19
INITIATION
BUCK
Neutral
Smart & Final Stores initiated with a Neutral at Buckingham
10/09/18
10/09/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Exelon (EXC) downgraded to Neutral from Overweight at JPMorgan and to Neutral from Buy at Citi. 2. CommScope (COMM) downgraded to Neutral from Buy at Goldman Sachs with analyst Mark Delaney saying he views the company's fundamental environment as "mixed" and views the stock's valuation as fair at current levels. 3. Mylan (MYL) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst David Risinger saying recent generics trends leave him seeing downside risk to consensus forecasts and Mylan's 2018 guidance. 4. Blackbaud (BLKB) downgraded to Market Perform from Outperform at Raymond James and JMP Securities as well as to Hold from Buy at Benchmark. 5. Kroger (KR) downgraded to Sell from Hold at Deutsche Bank while Smart & Final Stores (SFS) was downgraded to Hold from Buy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/09/18
DBAB
10/09/18
DOWNGRADE
Target $6
DBAB
Hold
Deutsche downgrades Smart & Final to Hold on investments, tough compares
Deutsche Bank analyst Paul Trussell downgraded Smart & Final Stores to Hold from Buy and lowered his price target for the shares to $6 from $9. The company's omnichannel and e-commerce investments could further dilute EBIT margins, Trussell tells investors in a research note. Further, Smart & Final is facing "very tough" compares ahead "with lagging inflation and no clear catalyst" to drive sales, the analyst adds. He expects the company's valuation to remain discounted in the difficult promotional and investment cycle.
02/07/19
BUCK
02/07/19
INITIATION
Target $6.75
BUCK
Neutral
Smart & Final Stores initiated with a Neutral at Buckingham
Buckingham analyst Bob Summers started Smart & Final Stores with a Neutral rating and $6.75 price target. The analyst is concerned "pressure points" from competitive activity and cannibalization will persist and he does not view the current valuation as "overly accommodating."
AMOT Allied Motion
$41.68

0.42 (1.02%)

10/29/18
DOTC
10/29/18
UPGRADE
DOTC
Buy
Allied Motion upgraded to Buy from Neutral at Dougherty
12/07/18
CHLM
12/07/18
NO CHANGE
Target $66
CHLM
Buy
Allied Motion price target raised to $66 from $62 at Craig-Hallum
Craig-Hallum analyst Greg Palm maintained a Buy rating on Allied Motion and raised his price target to $66 from $62 following the "solidly accretive" acquisition of TCI, which adds a complementary product portfolio, end market diversification and potential for significant long term synergies. In a research note to investors, Palm, who says Applied Motion is a top idea, says management has created substantial shareholder value over time with accretive M&A and says this acquisition appears to be no different.
11/02/18
CHLM
11/02/18
NO CHANGE
Target $62
CHLM
Buy
Allied Motion price target raised to $62 from $58 at Craig-Hallum
Craig-Hallum analyst Greg Palm maintained a Buy rating on Allied Motion and raised his price target to $62 from $58 following yesterday's "excellent" results. In a research note to investors, Palm says he sees additional means for upside including upward earnings revisions, continued macro strength, new business awards, and M&A, and calls Allied Motion a "top idea."
GDS GDS Holdings
$35.06

-0.38 (-1.07%)

09/10/18
09/10/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NMI Holdings (NMIH) initiated with an Overweight at Barclays. 2. Aridis Pharmaceuticals (ARDS) initiated with an Outperform at Northland, an Overweight at Cantor Fitzgerald, and a Buy at Laidlaw. 3. Central Garden & Pet (CENT) initiated with a Buy at BofA/Merrill. 4. GDS Holdings (GDS) initiated with an Outperform at Cowen. 5. Overstock.com (OSTK) assumed with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/18/18
RHCO
09/18/18
INITIATION
Target $46
RHCO
Buy
GDS Holdings initiated with a Buy at SunTrust
SunTrust analyst Greg Miller initated GDS Holdings with a Buy rating and a price target of $46 as part of his broader research coverage launch into Data Centers. The analyst contends that the company is a "pure-play Chinese data center company" with "appropriate risk tolerance exposure to the fastest-growing data center market in the world". Miller notes that GDS is a market share leader in China, "quickly becoming the provider of choice to China's major cloud and internet companies". The analyst believes that the company will outgrow its peers and produce "strong" operating leverage and free cash flows.
01/14/19
MSCO
01/14/19
INITIATION
Target $38
MSCO
Overweight
GDS Holdings started at Overweight, named tactical idea at Morgan Stanley
Morgan Stanley analyst Yang Liu initiated GDS Holdings with an Overweight rating and $38 price target and named the stock as a Research Tactical Idea, stating that he believes the shares will rise in absolute terms over the next 60 days. The high visibility of GDS's "rapid EBITDA growth" is underappreciated and the market's concerns about cloud demand are overdone, Liu tells investors.
09/20/18
BREN
09/20/18
INITIATION
Target $16
BREN
Sell
GDS Holdings initiated with a Sell at Berenberg
Berenberg analyst Nate Crossett started GDS Holdings with a Sell rating and $16 price target.
VKTX Viking Therapeutics
$8.25

0.28 (3.51%)

01/17/19
RILY
01/17/19
NO CHANGE
Target $16
RILY
Buy
Viking selloff on Citron's Ligand report overdone, says B. Riley FBR
B. Riley FBR analyst Mayank Mamtani views the selloff yesterday in shares of Viking Therapeutics (VKTX) after Citron Research published a short report on Ligand Pharmaceuticals (LGND), the company's largest shareholder, as overdone. Interestingly, Ligand values Viking at a 10 times higher valuation than current trading levels, Mamtani tells investors in a research note. The analyst, whose firm does not cover Ligand, believes the report supports his thesis of Viking being an undervalued nonalcoholic steatohepatitis story. Additionally, competitor Lipocine's (LPCN) fat reduction data this morning, "while surprisingly positive," fell short of meeting/exceeding the 10.6% absolute fat reduction data reported from Viking in a Phase IIa study of early NASH patients, says Mamtani. He believes Viking Therapeutics maintains its "best in class status" and reiterates a Buy rating on the shares with a $16 price target. The stock in atfernoon trading is up 4%, or 35c, to $8.35.
02/12/19
WBLR
02/12/19
NO CHANGE
WBLR
Viking could emerge as 'prime' buyout target for Gilead, says William Blair
Given Gilead Sciences' (GILD) leadership position in liver diseases and the significant resources that the company has devoted in the development of nonalcoholic steatohepatitis, last night's clinical setback "will likely reinvigorate" the company's willingness to augment its NASH pipeline, William Blair analyst Andy Hsieh tells investors in a research note. The analyst believes Gilead's Phase 3 failure could have a positive read-through to Viking Therapeutics (VKTX), which he notes is one of the only two beta-selective thyroid hormone receptor agonists in clinical testing. Viking's VK2809 demonstrated highly competitive data in reducing liver fat while maintaining a benign tolerability profile, Hsieh contends. Pending positive results from the company's Phase IIb study involving biopsy-confirmed NASH patients, he believes Viking Therapeutics "could emerge as a prime M&A target." The analyst keeps an Outperform rating on the shares. Viking in premarket trading is up 7% to $8.71.
02/22/19
LEER
02/22/19
INITIATION
Target $10
LEER
Market Perform
Viking Therapeutics initiated with a Market Perform at SVB Leerink
SVB Leerink analyst Pasha Sarraf initiated Viking Therapeutics with a Market Perform rating and $10 price target, telling investors in a research note that Viking is positioning VK2809, a hepatic prodrug, thyroid receptor beta-selective agonist for NASH, as it pursues an IND with the GI division, to start Phase 2b trials this year. Sarraf says he is positive on the immunology sector with its diverse indications, continuous innovation, and deep expertise, and is looking long for opportunities in challenging immuno-metabolism and metabolism sectors, in areas like NASH, obesity and diabetes.
12/12/18
12/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Foamix (FOMX) initiated with a Buy at BofA/Merrill. 2. Jazz Pharmaceuticals (JAZZ) initiated with an Outperform at Oppenheimer while GW Pharmaceuticals (GWPH) was initiated with a Perform. 3. Six Flags (SIX) initiated with a Buy at Berenberg. 4. iQIYI (IQ) initiated with a Hold at HSBC. 5. Intercept (ICPT), Viking Therapeutics (VKTX), and Galmed (GLMD) were initiated with a Buy at B. Riley FBR, while Madrigal Pharmaceuticals (MDGL) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AXAS Abraxas Petroleum
$1.34

0.07 (5.51%)

12/06/18
SPHN
12/06/18
INITIATION
Target $3
SPHN
Equal Weight
Abraxas Petroleum initiated with an Equal Weight at Stephens
Stephens analysts Gail Nicholson and Drew Lipke began coverage of the E&P sector with a positive outlook, starting Abraxas Petroleum with an Equal Weight rating and $3 price target.
LGCY Legacy Reserves
$1.39

0.12 (9.45%)

09/20/18
GHSC
09/20/18
INITIATION
Target $5
GHSC
Neutral
Legacy Reserves initiated with a Neutral at Seaport Global
Seaport Global analyst Mike Kelly initiated Legacy Reserves with a Neutral and $5 price target citing below average organic Permian growth.
09/19/18
GHSC
09/19/18
INITIATION
Target $5
GHSC
Neutral
Legacy Reserves initiated with a Neutral at Seaport Global
Price target $5.
05/14/18
UBSW
05/14/18
UPGRADE
UBSW
Neutral
Legacy Reserves upgraded to Neutral from Sell at UBS
09/20/18
09/20/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Westport (WPRT) initiated with a Buy at H.C. Wainwright. 2. Legacy Reserves (LGCY) initiated with a Neutral at Seaport Global. 3. Tandem Diabetes (TNDM) initiated with a Buy at Craig-Hallum. 4. Bio-Rad (BIO) initiated with an Equal Weight at Morgan Stanley. 5. Brookfield (BAM) initiated with an Outperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
RRTS Roadrunner
$0.49

-0.0058 (-1.18%)

01/15/19
STFL
01/15/19
INITIATION
STFL
Hold
Roadrunner resumed with a Hold at Stifel
Stifel analyst J. Bruce Chan resumed Roadrunner with a Hold rating and 61c price target, stating that the company has a credible go-to-market strategy but he also views it as an "acquisition roll-up with significant risks."

TODAY'S FREE FLY STORIES

21:25
03/25/19
03/25
21:25
03/25/19
21:25
General news
Fed's Rosengren warned that U.S. Q1 growth is likely to be weak »

Fed's Rosengren…

BBBY

Bed Bath & Beyond

$13.87

0.17 (1.24%)

20:44
03/25/19
03/25
20:44
03/25/19
20:44
Periodicals
Activist firms seek to replace Bed Bath & Beyond board, CEO, WSJ says »

Activist funds -Legion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Apr

RTN

Raytheon

$180.58

-0.82 (-0.45%)

, BA

Boeing

$370.52

8.37 (2.31%)

20:36
03/25/19
03/25
20:36
03/25/19
20:36
Hot Stocks
Raytheon kill vehicle hits ICBM target in first dual-salvo test »

For the first time, the…

RTN

Raytheon

$180.58

-0.82 (-0.45%)

BA

Boeing

$370.52

8.37 (2.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

20:35
03/25/19
03/25
20:35
03/25/19
20:35
General news
The "Summary of Opinions" from the BoJ's March meeting »

The "Summary of…

WHD

Cactus

$36.03

1.225 (3.52%)

20:27
03/25/19
03/25
20:27
03/25/19
20:27
Hot Stocks
Cactus VP of Operations sells 229K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$56.67

-0.065 (-0.11%)

, MKC

McCormick

$143.88

1.58 (1.11%)

20:25
03/25/19
03/25
20:25
03/25/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CCL

Carnival

$56.67

-0.065 (-0.11%)

MKC

McCormick

$143.88

1.58 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 26

    Mar

  • 27

    Mar

CRTO

Criteo

$21.99

-3.4 (-13.39%)

20:19
03/25/19
03/25
20:19
03/25/19
20:19
Downgrade
Criteo rating change at KeyBanc »

Criteo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

$0.00

(0.00%)

20:02
03/25/19
03/25
20:02
03/25/19
20:02
Periodicals
Samsung sees weaker environment for display, memory in Q1, Bloomberg says »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$370.52

8.37 (2.31%)

19:51
03/25/19
03/25
19:51
03/25/19
19:51
Hot Stocks
U.S. MDA and Boeing Complete Historic Missile Defense Test »

The U.S. Missile Defense…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

MCD

McDonald's

$185.66

-1.11 (-0.59%)

19:49
03/25/19
03/25
19:49
03/25/19
19:49
Periodicals
McDonald's purchase price of Dynamic Yield above $300M, Bloomberg says »

The purchase of Dynamic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 28

    May

SSNLF

Samsung

$0.00

(0.00%)

19:32
03/25/19
03/25
19:32
03/25/19
19:32
Periodicals
Breaking Periodicals news story on Samsung »

Samsung sees Q1 below…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWR

American States Water

$71.51

0.505 (0.71%)

19:22
03/25/19
03/25
19:22
03/25/19
19:22
Hot Stocks
American States Water CEO sells 12.4K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$56.35

-1.38 (-2.39%)

19:10
03/25/19
03/25
19:10
03/25/19
19:10
Hot Stocks
Methanex confirms receipt of director nominees notice from M&G »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$34.14

0.81 (2.43%)

, SAEX

SAExploration

$4.03

0.13 (3.33%)

18:55
03/25/19
03/25
18:55
03/25/19
18:55
Hot Stocks
Fly Intel: After Hours Movers »

DOWN AFTER EARNINGS:…

BECN

Beacon Roofing

$34.14

0.81 (2.43%)

SAEX

SAExploration

$4.03

0.13 (3.33%)

IQ

iQIYI

$24.01

-0.86 (-3.46%)

MYOK

MyoKardia

$51.87

-2.44 (-4.49%)

CTMX

CytomX Therapeutics

$10.76

0.33 (3.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 26

    Mar

  • 21

    May

  • 27

    Mar

HPQ

HP Inc.

$18.97

-0.4 (-2.07%)

18:48
03/25/19
03/25
18:48
03/25/19
18:48
Periodicals
HP lawyer tells court Autonomy's Lynch inflated sales data, Reuters says »

A lawyer for HP told a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

PEGA

Pegasystems

$63.61

-0.27 (-0.42%)

18:45
03/25/19
03/25
18:45
03/25/19
18:45
Hot Stocks
Pegasystems CEO: We are massively changing our marketing strategy »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

SMTC

Semtech

$52.59

-0.38 (-0.72%)

18:32
03/25/19
03/25
18:32
03/25/19
18:32
Hot Stocks
Semtech CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

TMO

Thermo Fisher

$268.89

5.015 (1.90%)

18:24
03/25/19
03/25
18:24
03/25/19
18:24
Hot Stocks
Thermo Fisher CEO: We have a very disciplined M&A process »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

18:24
03/25/19
03/25
18:24
03/25/19
18:24
Periodicals
Parliament forces votes on Brexit plan options, Bloomberg reports »

Lawmakers of U.K.…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.99

-0.56 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$185.66

-1.11 (-0.59%)

18:23
03/25/19
03/25
18:23
03/25/19
18:23
Hot Stocks
McDonald's to acquire Dynamic Yield, terms not stated »

McDonald's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 28

    May

BA

Boeing

$370.52

8.37 (2.31%)

18:22
03/25/19
03/25
18:22
03/25/19
18:22
Periodicals
Boeing software fix to prevent repeated activiation of MCAS, Reuters says »

A Boeing software repair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ACHC

Acadia

$29.47

-0.59 (-1.96%)

17:58
03/25/19
03/25
17:58
03/25/19
17:58
Hot Stocks
Acadia says President Brett Turner leaving by mutual agreement »

Brent Turner, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.78

-2.33 (-1.22%)

17:41
03/25/19
03/25
17:41
03/25/19
17:41
Recommendations
Apple analyst commentary at Piper Jaffray »

Apple price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

ZFGN

Zafgen

$2.70

-0.15 (-5.26%)

17:38
03/25/19
03/25
17:38
03/25/19
17:38
Hot Stocks
Armistice Capital reports 5.6% passive stake in Zafgen »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$268.56

0.27 (0.10%)

17:36
03/25/19
03/25
17:36
03/25/19
17:36
Hot Stocks
Northrop Grumman awarded $245.05M Navy contract modification »

Northrop Grumman has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.